Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety

Avery D Posey; Henrik Clausen; Carl H June

doi:10.1016/j.immuni.2016.10.015

Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety

Avery D Posey, Henrik Clausen, Carl H June

Glycomics Program

19 Citations (Scopus)

Abstract

Genetically modified T cells expressing chimeric antigen receptors (CARs) demonstrate potent clinical antitumor effects in a variety of blood cancers. However, clinical activity in solid tumors has been disappointing and toxicity has been a serious concern (Lamers et al., 2013; Morgan et al., 2010). We recently found that a CAR composed of a scFv antibody fragment specific for the Tn-glycoform of MUC1 had potent activity in preclinical models of blood cancer and adenocarcinoma (Posey et al., 2016).

Original language	English
Journal	Immunity
Volume	45
Issue number	5
Pages (from-to)	947-948
Number of pages	2
ISSN	1074-7613
DOIs	https://doi.org/10.1016/j.immuni.2016.10.015
Publication status	Published - 15 Nov 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.immuni.2016.10.015

http://www.cell.com/article/S1074761316304265/pdf

Cite this

@article{1a92a8f347554148b49f7d120d6772cc,

title = "Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety",

abstract = "Genetically modified T cells expressing chimeric antigen receptors (CARs) demonstrate potent clinical antitumor effects in a variety of blood cancers. However, clinical activity in solid tumors has been disappointing and toxicity has been a serious concern (Lamers et al., 2013; Morgan et al., 2010). We recently found that a CAR composed of a scFv antibody fragment specific for the Tn-glycoform of MUC1 had potent activity in preclinical models of blood cancer and adenocarcinoma (Posey et al., 2016).",

author = "Posey, {Avery D} and Henrik Clausen and June, {Carl H}",

note = "Copyright {\textcopyright} 2016. Published by Elsevier Inc.",

year = "2016",

month = nov,

day = "15",

doi = "10.1016/j.immuni.2016.10.015",

language = "English",

volume = "45",

pages = "947--948",

journal = "Immunity",

issn = "1074-7613",

publisher = "Cell Press",

number = "5",

}

TY - JOUR

T1 - Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells

T2 - Specificity Is the Key to Safety

AU - Posey, Avery D

AU - Clausen, Henrik

AU - June, Carl H

PY - 2016/11/15

Y1 - 2016/11/15

N2 - Genetically modified T cells expressing chimeric antigen receptors (CARs) demonstrate potent clinical antitumor effects in a variety of blood cancers. However, clinical activity in solid tumors has been disappointing and toxicity has been a serious concern (Lamers et al., 2013; Morgan et al., 2010). We recently found that a CAR composed of a scFv antibody fragment specific for the Tn-glycoform of MUC1 had potent activity in preclinical models of blood cancer and adenocarcinoma (Posey et al., 2016).

AB - Genetically modified T cells expressing chimeric antigen receptors (CARs) demonstrate potent clinical antitumor effects in a variety of blood cancers. However, clinical activity in solid tumors has been disappointing and toxicity has been a serious concern (Lamers et al., 2013; Morgan et al., 2010). We recently found that a CAR composed of a scFv antibody fragment specific for the Tn-glycoform of MUC1 had potent activity in preclinical models of blood cancer and adenocarcinoma (Posey et al., 2016).

U2 - 10.1016/j.immuni.2016.10.015

DO - 10.1016/j.immuni.2016.10.015

M3 - Letter

C2 - 27851918

SN - 1074-7613

VL - 45

SP - 947

EP - 948

JO - Immunity

JF - Immunity

IS - 5

ER -

Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this